CRISPR Therapeutics (CRSP) – Press Releases
-
CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference
-
CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
-
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
-
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit
-
CRISPR Therapeutics Announces $280 Million Registered Direct Offering
-
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TD
-
CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
-
CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook
-
CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
-
CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease
-
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell
-
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
-
CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023
-
CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease
-
CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)
-
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
-
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
-
CRISPR Therapeutics Announces Leadership Transition
-
CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference
-
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
-
CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
-
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
-
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
-
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
-
CRISPR Therapeutics to Participate Upcoming Investor Conferences
-
CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference
-
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Th
-
CRISPR Therapeutics Announces Departure of Board Member
-
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
-
CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting
-
CRISPR Therapeutics Announces Transition of Chief Financial Officer
-
CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference
-
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
-
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
-
CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference
-
CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development
-
CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110®
-
Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
-
CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference
-
CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
-
CRISPR Therapeutics Announces Poster Presentation on CTX110® at the American Society of Hematology (ASH) 2022 Annual Meeting
-
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
-
CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer
-
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
-
CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy
-
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)
-
Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
-
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
Back to CRSP Stock Lookup
